KZIA

Kazia Therapeutics
KZIA

$0.3303

2.85%

Market Cap: $11M

About: Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Employees: 9

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% more funds holding

Funds holding: 11 [Q1] → 11 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.08% less ownership

Funds ownership: 0.22% [Q1] → 0.13% (-0.08%) [Q2]

49% less capital invested

Capital invested by funds: $177K [Q1] → $89.5K (-$87.3K) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$2

506%

upside

Avg. target

$2

506%

upside

High target

$2

506%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Sean Lee

56% 1-year accuracy

9 / 16 met price target

506%upside

$2

Buy

Reiterated

12 Jul 2024

See Analyst Rankings

Financial journalist opinion

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

SYDNEY , Sept. 12, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination).

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

Australian biotech company Kazia Therapeutics (NASDAQ: KZIA ) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib. The positive results extended the life of patients by over three months compared to the current standard of care.

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers?

Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

Zacks Investment Research

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher

If you've read all the warnings and still want to jump into some of the top penny stocks to buy, focus on the key fundamentals. That includes its earnings numbers, business models, product pipelines and what market they're part of.

From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher

KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains

Kazia Therapeutics (NASDAQ: KZIA ) stock is continuing to rally on Thursday after the company reported positive alongside clinical trial data yesterday. The Kazia Therapeutics clinical trial covered the company's paxalisib as a treatment of glioblastoma.

KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains

Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment

Kazia Therapeutics Limited KZIA released results on Wednesday from the GBM-AGILE Phase 2/3 study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma, a type of brain cancer.

Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment

Why Is Kazia Therapeutics (KZIA) Stock Up 300% Today?

Kazia Therapeutics (NASDAQ: KZIA ) stock is soaring higher on Wednesday after the oncology-focused biotechnology company provided results from a Phase II/III clinical trial. These results concern the effectiveness of paxalisib as a treatment of glioblastoma versus the standard of care (SOC).

Why Is Kazia Therapeutics (KZIA) Stock Up 300% Today?

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma SYDNEY , July 10, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma (NCT03522298), a life-threatening brain cancer, where there is an urgent unmet need for new therapeutics. GBM AGILE STUDY GBM AGILE is an adaptive phase II/III global trial sponsored by the Global Coalition for Adaptive Research (GCAR), a nonprofit organization comprised of some of the world's foremost clinical, translational, and basic science researchers, from institutions such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

See News Rankings